Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in J Exp Med Retrieve available abstracts of 68 articles: HTML format

Single Articles

November 2023
1. RUTERBUSCH MJ, Hondowicz BD, Takehara KK, Pruner KB, et al
   Allergen exposure functionally alters influenza-specific CD4+ Th1 memory cells in the lung.
   J Exp Med. 2023;220:e20230112.
   PubMed     Abstract available
   
   
   September 2023
2. WANG Z, Muecksch F, Raspe R, Johannsen F, et al
   Memory B cell development elicited by mRNA booster vaccinations in the elderly.
   J Exp Med. 2023;220:e20230668.
   PubMed     Abstract available
   
   
   August 2023
3. RYBKINA K, Bell JN, Bradley MC, Wohlbold T, et al
   SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19.
   J Exp Med. 2023;220:e20221518.
   PubMed     Abstract available
   
   
   
4. LIN YS, Chang YC, Chao TL, Tsai YM, et al
   The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage.
   J Exp Med. 2023;220:e20220727.
   PubMed     Abstract available
   
   
   
5. GILBERTSON B, Subbarao K
   Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potential.
   J Exp Med. 2023;220:e20230447.
   PubMed     Abstract available
   
   
   May 2023
6. GARCIA-GARCIA A, Perez de Diego R, Flores C, Rinchai D, et al
   Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia.
   J Exp Med. 2023;220:e20220170.
   PubMed     Abstract available
   
   
   March 2023
7. KAISER KA, Loffredo LF, Santos-Alexis KL, Ringham OR, et al
   Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells.
   J Exp Med. 2023;220:e20221462.
   PubMed     Abstract available
   
   
   February 2023
8. ONNIS A, Andreano E, Cassioli C, Finetti F, et al
   SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly.
   J Exp Med. 2023;220.
   PubMed     Abstract available
   
   
   
9. INOUE T, Shinnakasu R, Kawai C, Yamamoto H, et al
   Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees.
   J Exp Med. 2023;220:e20221786.
   PubMed     Abstract available
   
   
   January 2023
10. SOKAL A, Bastard P, Chappert P, Barba-Spaeth G, et al
    Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
    J Exp Med. 2023;220.
    PubMed     Abstract available
    
    
    December 2022
11. BEER J, Crotta S, Breithaupt A, Ohnemus A, et al
    Impaired immune response drives age-dependent severity of COVID-19.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
12. WANG Z, Zhou P, Muecksch F, Cho A, et al
    Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    November 2022
13. SHEMESH A, Su Y, Calabrese DR, Chen D, et al
    Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcepsilonRIgamma expression.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
14. ZHANG Q, Pizzorno A, Miorin L, Bastard P, et al
    Autoantibodies against type I IFNs in patients with critical influenza pneumonia.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    October 2022
15. LIM JME, Tan AT, Le Bert N, Hang SK, et al
    SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
16. WANG Z, Muecksch F, Muenn F, Cho A, et al
    Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    September 2022
17. AGUDELO M, Muecksch F, Schaefer-Babajew D, Cho A, et al
    Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
18. HALE M, Netland J, Chen Y, Thouvenel CD, et al
    IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    August 2022
19. ZHANG Q, Matuozzo D, Le Pen J, Lee D, et al
    Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
20. CHO A, Muecksch F, Wang Z, Ben Tanfous T, et al
    Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    July 2022
21. WARE CF, Croft M, Neil GA
    Realigning the LIGHT signaling network to control dysregulated inflammation.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
22. CAMPBELL TM, Liu Z, Zhang Q, Moncada-Velez M, et al
    Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
23. PLANCHAIS C, Fernandez I, Bruel T, de Melo GD, et al
    Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    June 2022
24. DUNCAN CJA, Skouboe MK, Howarth S, Hollensen AK, et al
    Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
25. CASTLEMAN MJ, Stumpf MM, Therrien NR, Smith MJ, et al
    SARS-CoV-2 infection relaxes peripheral B cell tolerance.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
26. MEYTS I
    Null IFNAR1 and IFNAR2 alleles are surprisingly common in the Pacific and Arctic.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    April 2022
27. PUEL A, Bastard P, Bustamante J, Casanova JL, et al
    Human autoantibodies underlying infectious diseases.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    February 2022
28. ZHANG B, Zhang Y, Xiong L, Li Y, et al
    CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
29. HOSTE L, Roels L, Naesens L, Bosteels V, et al
    TIM3+ TRBV11-2 T cells and IFNgamma signature in patrolling monocytes and CD16+ NK cells delineate MIS-C.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    
30. HILLIGAN KL, Namasivayam S, Clancy CS, O'Mard D, et al
    Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    January 2022
31. MAO T, Israelow B, Lucas C, Vogels CBF, et al
    A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.
    J Exp Med. 2022;219.
    PubMed     Abstract available
    
    
    December 2021
32. SHINNAKASU R, Sakakibara S, Yamamoto H, Wang PH, et al
    Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
33. LU X, Hosono Y, Nagae M, Ishizuka S, et al
    Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
34. PYLE CJ, Labeur-Iurman L, Groves HT, Puttur F, et al
    Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    November 2021
35. RAPPE JCF, Finsterbusch K, Crotta S, Mack M, et al
    A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
36. FONSECA W, Malinczak CA, Fujimura K, Li D, et al
    Maternal gut microbiome regulates immunity to RSV infection in offspring.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    October 2021
37. DECKER T
    The early interferon catches the SARS-CoV-2.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
38. LOPEZ J, Mommert M, Mouton W, Pizzorno A, et al
    Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    September 2021
39. AHN M, Wang LF
    Translation from bats to humans beyond infectious diseases.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    August 2021
40. CHEEMARLA NR, Watkins TA, Mihaylova VT, Wang B, et al
    Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
41. WILK AJ, Lee MJ, Wei B, Parks B, et al
    Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    July 2021
42. BASTARD P, Orlova E, Sozaeva L, Levy R, et al
    Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
43. SOLFOROSI L, Kuipers H, Jongeneelen M, Rosendahl Huber SK, et al
    Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    June 2021
44. LANZ C, Schotsaert M, Magnus C, Karakus U, et al
    IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
45. SANCHO-SHIMIZU V, Brodin P, Cobat A, Biggs CM, et al
    SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    May 2021
46. ANDREANO E, Rappuoli R
    Immunodominant antibody germlines in COVID-19.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
47. LE BERT N, Clapham HE, Tan AT, Chia WN, et al
    Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
48. MERAD M, Vabret N
    Highlights from a year in a pandemic.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
49. BAUM A, Kyratsous CA
    SARS-CoV-2 spike therapeutic antibodies in the age of variants.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
50. KEDL RM
    Down but far from out: The durability of SARS-CoV-2 immunity after asymptomatic infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    April 2021
51. ZHUANG Z, Lai X, Sun J, Chen Z, et al
    Mapping and role of T cell response in SARS-CoV-2-infected mice.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
52. ONODI F, Bonnet-Madin L, Meertens L, Karpf L, et al
    SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
53. BRETON G, Mendoza P, Hagglof T, Oliveira TY, et al
    Persistent cellular immunity to SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
54. BASTARD P, Michailidis E, Hoffmann HH, Chbihi M, et al
    Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
55. POON MML, Farber DL
    Lasting memories of SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
56. MCCARTY NA
    Breathe-Your immune system is counting on it.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    March 2021
57. SCHAFER A, Muecksch F, Lorenzi JCC, Leist SR, et al
    Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
58. LU Y, Jiang R, Freyn AW, Wang J, et al
    CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
59. RODRIGUES TS, de Sa KSG, Ishimoto AY, Becerra A, et al
    Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
60. BRYANT C
    COVID-19 stokes inflammasomes.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
61. SONG E, Zhang C, Israelow B, Lu-Culligan A, et al
    Neuroinvasion of SARS-CoV-2 in human and mouse brain.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    
62. NIMMERJAHN F, Ravetch JV
    Four keys to unlock IgG.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    January 2021
63. PAIK DH, Farber DL
    Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity.
    J Exp Med. 2021;218.
    PubMed     Abstract available
    
    
    December 2020
64. VERAS FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, et al
    SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.
    J Exp Med. 2020;217.
    PubMed     Abstract available
    
    
    
65. RADERMECKER C, Detrembleur N, Guiot J, Cavalier E, et al
    Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19.
    J Exp Med. 2020;217.
    PubMed     Abstract available
    
    
    
66. MAJOR J, Wack A
    An ace model for SARS-CoV-2 infection.
    J Exp Med. 2020;217.
    PubMed     Abstract available
    
    
    
67. KOAY HF, Fulford TS, Godfrey DI
    An unconventional view of COVID-19 T cell immunity.
    J Exp Med. 2020;217.
    PubMed     Abstract available
    
    
    November 2020
68. KIM JH
    SARS-CoV-2 vaccine development, access, and equity.
    J Exp Med. 2020;217.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: